

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

APPLICANT : Alistair Dixon, et al. EXAMINER :
SERIAL NO. : 10/031180 ART UNIT :
FILED : January 16, 2002 PAPER NO :
FOR : METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS

Statement as Provided by 37 CFR 1.97(b)

Commissioner for Patents
Washington, D.C. 20231


Dear Sir:

The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of the first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

It is understood by the Applicants that this paper requires no fee; however, authorization is given to charge any necessary filing fees and any additional fees or credit any overpayment to Deposit Account 23-0455.

Respectfully submitted,

Dated: May 16, 2002



Suzanne M. Harvey
Registration No. 42,640
Warner-Lambert Company
2800 Plymouth Road
Ann Arbor, MI 48105
Telephone: (734) 622-2658
Facsimile: (734) 622-1553

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/031,180
				Filing Date	January 16, 2002
				First Named Inventor	Alistair Dixon, et al.
				Group Art Unit	
				Examiner Name	
Sheet	1	of	2	Attorney Docket Number	A0000096-01-SMH

[illegible][illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

USSN 10/031,180 PD-A00000096-01-SM
Express Mail No. EF220788503US

Please type a plus sign (+) inside this box → +

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
		Application Number	10/031,180		
		Filing Date	January 16, 2002		
		First Named Inventor	Alistair Dixon, et al.		
		Group Art Unit			
		Examiner Name			
Sheet	2	of	2	Attorney Docket Number	A0000096-01-SMH

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		PCT International Search Report PCT/US00/18347	
		N. S. DUESBERY, et al., "MEK Wars, a new front in the Battle Against Cancer", Nature Medicine, July 1999, pp 736-737, Vol. 5, No. 7	
		J. V. DUNCIA, et al., "MEK Inhibitors: The Chemistry and Biological Activity of U0126, Its Analogs, and Cyclization Products", Bioorganic & Medicinal Chemistry Letters, 1998, pp 2839-2844, No. 8	
		A.N. GAIDUKEVICH, et al., "Synthesis and Biological Activity of N-Phenylanthranilic Acid Derivatives", STN Chemical Abstracts, September 16, 1985, Vol. 1, No. 103, Abstract Only	
		R. J. GRYGLEWSKI, "Structure-activity Relations of Some Prostaglandin Synthetase Inhibitors", Database Chemabs, 1974, Accession No. 83:126083 Abstract Only	
		M. KHALIFA, et al., "Synthesis and Biological Activity of Certain Derivatives of 2,4-Dioxo-1,2,3,4-tetrahydroquinazoline* Part 2", Egypt J. Chem., 1982, pp 285-291, Vol. 25, No. 3	
		M. KHALIFA, et al., "Synthesis and Biological Activity of Certain Derivatives of 2,4-Dioxo-1,2,3,4-tetrahydroquinazoline", Pharmazie, 1982, pp 115-117, Vol. 37, No. 2	
		N. A. MOKHORT, "Dependence Between Structure, Anitnflammatory, Analgesic, and Antipyretic Actions in N-aromatic Derivatives of Anthranilic Acid", Chemabs, 1972, Accession No. 1972:121461 Abstract Only	
		RU-RONG JI, et al., "Nociceptive-specific Activation of ERK in Spinal Neurons Contributes to Pain Hypersensitivity", Nature Neuroscience, December 1999, pp 1114-1119, Vol. 2, No. 12	
		I. S. SHUL'GA, et al., "Synthesis and Physicochemcial and Biological Properties of Diphenylamine-2-carboxylic Acid Derivatives", STN Chemical Abstracts, October 24, 1988, Vol. 17, No. 109 Abstract Only	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.